CIK 1792206
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 92.32% | 7 |
| Health Care Providers & Services | 5.65% | 1 |
| Unclassified | 2.02% | 1 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | ALMS | ALUMIS INC. | Health Care | 47.94% |
| 2 | CGON | CG Oncology, Inc. | Health Care | 25.08% |
| 3 | IRON | Disc Medicine, Inc. | Health Care | 8.83% |
| 4 | HIMS | Hims & Hers Health, Inc. | Health Care | 5.65% |
| 5 | EIKN | Eikon Therapeutics, Inc. | Health Care | 5.15% |
| 6 | LYEL | Lyell Immunopharma, Inc. | Health Care | 3.53% |
| 7 | PHVS | PHARVARIS N V | Unclassified | 2.02% |
| 8 | NRIX | Nurix Therapeutics, Inc. | Health Care | 1.52% |
| 9 | MAZE | Maze Therapeutics, Inc. | Health Care | 0.29% |
8/9 names classified · sector 98.0% of weight · industry 98.0% · mkt cap 98.0%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 98.0% of the book is sector-classified (unclassified names shown, never dropped).
Only 6% of book weight classified — the grid is NOT representative of the whole book.
Classified: 5.7% of book weight (1/9 names) · unclassified 94.3%: ALMS, CGON, IRON, EIKN, LYEL, PHVS, NRIX, MAZE. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | ALMSALUMIS INC | 5,896,995 | $130M | 47.9% | ADD 2% |
| 2 | CGONCG ONCOLOGY INC | 1,004,050 | $68M | 25.1% | HOLD |
| 3 | IRONDISC MEDICINE INC | 374,069 | $24M | 8.8% | ADD 25% |
| 4 | HIMSHIMS & HERS HEALTH INC | 738,151 | $15M | 5.7% | ADD 170% |
| 5 | EIKNEIKON THERAPEUTICS INC | 1,318,983 | $14M | 5.1% | NEW |
| 6 | LYELLYELL IMMUNOPHARMA INC | 477,078 | $10M | 3.5% | HOLD |
| 7 | PHVSPHARVARIS N V | 194,125 | $5M | 2.0% | NEW |
| 8 | NRIXNURIX THERAPEUTICS INC | 265,000 | $4M | 1.5% | NEW |
| 9 | MAZEMAZE THERAPEUTICS INC | 25,905 | $773,264 | 0.3% | TRIM −70% |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| ALMSALUMIS INC | 5.8M | 5.8M | 5.8M | 5.8M | 5.8M | 5.9M | $130M |
| CGONCG ONCOLOGY INC | 693K | 859K | 1.0M | 1.0M | 1.0M | 1.0M | $68M |
| IRONDISC MEDICINE INC | 299K | 299K | 299K | 299K | 299K | 374K | $24M |
| HIMSHIMS & HERS HEALTH INC | 940K | 273K | 273K | 273K | 273K | 738K | $15M |
| EIKNEIKON THERAPEUTICS INC | — | — | — | — | — | 1.3M | $14M |
| LYELLYELL IMMUNOPHARMA INC | — | — | 407K | 477K | 477K | 477K | $10M |
| PHVSPHARVARIS N V | — | — | — | — | — | 194K | $5M |
| NRIXNURIX THERAPEUTICS INC | — | — | — | — | — | 265K | $4M |
| MAZEMAZE THERAPEUTICS INC | — | 345K | 345K | 86K | 86K | 26K | $773,264 |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
